Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005042-42
    Sponsor's Protocol Code Number:CURF18PSM0001
    National Competent Authority:Austria - BASG
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-05-11
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedAustria - BASG
    A.2EudraCT number2020-005042-42
    A.3Full title of the trial
    Prospective study of added value of florastamin (18F) PET/CT in localisation of clinically significant prostate cancer in patients with PI-RADS≤3 report of multi-parametric MRI, elevated serum PSA levels and/or PSA density and with clinical suspicion of prostate cancer
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Prospective study of added value of florastamin (18F) PET/CT in localisation of clinically significant prostate cancer in patients with negative or equivocal result of multi-parametric MRI, elevated serum PSA levels and/or PSA density and with clinical suspicion of prostate cancer
    A.3.2Name or abbreviated title of the trial where available
    Florastamin (18F) PET/CT vs. mpMRI in localisation of clinically significant prostate cancer
    A.4.1Sponsor's protocol code numberCURF18PSM0001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCURIUM Austria GmbH
    B.1.3.4CountryAustria
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCURIUM Austria GmbH
    B.4.2CountryAustria
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCURIUM Austria GmbH
    B.5.2Functional name of contact pointClinical Trials Information
    B.5.3 Address:
    B.5.3.1Street AddressGrazer Straße 18
    B.5.3.2Town/ cityHausmannstätten
    B.5.3.3Post codeA-8071
    B.5.3.4CountryAustria
    B.5.4Telephone number00436645315021
    B.5.5Fax number00433162843007
    B.5.6E-mailchantal.masungi@curiumpharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name(18F)-florastamin
    D.3.2Product code (18F)-FC303
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INN(18F)Florastamin
    D.3.9.3Other descriptive name(9S,13S)-1-(1-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylicacid
    D.3.9.4EV Substance CodeSUB221317
    D.3.10 Strength
    D.3.10.1Concentration unit GBq gigabecquerel(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number0.35 to 14
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product Yes
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Prostate cancer suspected clinically and on the basis of elevated serum Prostate Specific Antigen (PSA) levels and PSA density and with result of multiparametric Magnetic Resonance Imaging (mpMRI) of prostate gland scored ≤3 according to PI-RADS v2.1
    E.1.1.1Medical condition in easily understood language
    Prostate cancer suspected clinically and on the basis of elevated serum PSA levels and PSA density and with negative or equivocal result of Magnetic Resonance Imaging (MRI) of prostate gland
    E.1.1.2Therapeutic area Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10060862
    E.1.2Term Prostate cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10053838
    E.1.2Term Free prostate-specific antigen increased
    E.1.2System Organ Class 10022891 - Investigations
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10050321
    E.1.2Term Prostate examination
    E.1.2System Organ Class 10022891 - Investigations
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10029096
    E.1.2Term Neoplasm prostate
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10004385
    E.1.2Term Benign neoplasm of prostate
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • To analyse the patient-based sensitivity of florastamin (18F) PET/CT for localisation of csPCa in patients with elevated serum PSA levels and/or PSA density and with clinical suspicion of PCa and with report of mpMRI of prostate gland scored ≤3 according to PI-RADS v2.1
    • Analyse der patientenbasierten Empfindlichkeit von Florastamin (18F) PET / CT für die Lokalisierung von csPCa bei Patienten mit erhöhten Serum-PSA-Spiegeln und / oder PSA-Dichte und mit klinischem Verdacht auf PCa und mit einem Bericht über mpMRI der Prostata, der mit ≤3 bewertet wurde zu PI-RADS v2.1
    E.2.2Secondary objectives of the trial
    • To assess the patient anf the site-based specificity and positive and negative predictive value and site-based sensitivity of florastamin (18F) PET/CT for localisation of csPCa
    • To assess the net reclassification index (NRI) of florastamin (18F) for localisation of csPCa
    • To assess the frequency of impact of florastamin (18F) PET/CT on diagnostic thinking
    • To assess the frequency of impact of florastamin (18F) PET/CT on patient management.
    • To correlate the patient based diagnostic performance of florastamin (18F) PET/CT in detection of csPCa with prostate health index (PHI) when available
    • To correlate quantitative uptake of florastamin (18F) with diagnostic performances in localization of csPCa.
    • To confirm the safety profile of florastamin (18F)
    • To correlate quantitative uptake of florastamin (18F) with histopathological results
    • To refine the interpretation criteria of florastamin (18F) PET/CT
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Male gender;
    • Age ≥18 years;
    • PSA ≥10ng/mL and/or PSAD≥0.26 ng/mL2;
    • PI-RADS v2 ≤3 report of mpMRI performed less than 3 months prior inclusion;
    • Availability of mpMRI data for centralized reading;
    • Patient scheduled for biopsy or radical prostatectomy;
    • Signed informed consent;
    • Absence of any of the exclusion criteria.
    E.4Principal exclusion criteria
    • Absence of any of the inclusion criteria;
    • Hypersensitivity to active substance or any of excipients of investigational medicinal product
    • Life expectancy <6 months;
    • ECOG performance status >2.
    • Concomitant active malignancy
    • Past history of confirmed prostate cancer.
    E.5 End points
    E.5.1Primary end point(s)
    Localisation of csPCa by florastamin (18F) PET/CT in patients with elevated serum PSA levels and/or PSA density and with clinical suspicion of PCa. Percentage of true positive (TP) patients among TP divided by (TP + false negative (FN)).
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary endpoint will be evaluated on the basis of standard of truth during six month follow-up period in each included subject.
    For whole study, the primary endpoint will be assessed six months after inclusion of the last evaluable patient.
    E.5.2Secondary end point(s)
    • Percentage of true negative (TN) patients among TN divided by (TN + false positive (FP)).
    • Percentage of true positive (TP) sites among TP divided by (TP + false negative (FN)).
    • NRI of florastamin (18F).
    • Percentage of patients in whom the initially scheduled diagnostic thinking has been modified based on florastamin (18F) PET/CT results.
    • Percentage of patients in whom the therapeutic management of PCa has been modified based on florastamin (18F) PET/CT results.
    • Correlation of patient based diagnostic performance of florastamin (18F) PET/CT with PHI when available.
    • Quantitative uptake of florastamin (18F) by csPCa
    • Percentage adverse events observed during the first 24 hours florastamin (18F) administration.
    • Correlation of quantitative uptake of florastamin (18F) with histopathological results.
    • Establishment of interpretation criteria.
    E.5.2.1Timepoint(s) of evaluation of this end point
    • Impact of florastamin (18F) PET/CT on diagnostic thinking
    • Impact of florastamin (18F) PET/CT on patient management
    • Incidental finding(s) of florastamin (18F) PET/CT
    • Abnormality of biodistribution of florastamin (18F)
    • Adverse reaction(s) related with use of florastamin (18F)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis Yes
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Prospective comparative trial with diagnostic product with blind reading and with standard of truth
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    multiparametric Magnetic Resonance Imaging (mpMRI)
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Completion of standard of truth and six-month clinical follow-up period in last included and evaluable patient.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 60
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 11
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 71
    F.4.2.2In the whole clinical trial 71
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Not applicable
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-06-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-04-29
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:19:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA